相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification
Narasimhan P. Agaram et al.
MODERN PATHOLOGY (2019)
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group
Dana L. Casey et al.
CANCER (2019)
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Douglas S. Hawkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic Relevance of Early Radiologic Response to Induction Chemotherapy in Pediatric Rhabdomyosarcoma: A Report From the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 Study
Bas Vaarwerk et al.
CANCER (2018)
The prognostic value of early radiographic response in children and adolescents with embryonal rhabdomyosarcoma stage IV, metastases confined to the lungs: A report from the Cooperative Weichteilsarkom Studiengruppe (CWS)
Monika Sparber-Sauer et al.
PEDIATRIC BLOOD & CANCER (2017)
The Role of 18F-FDG-PET/CT in Pediatric Sarcoma
Douglas J. Harrison et al.
SEMINARS IN NUCLEAR MEDICINE (2017)
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes
Bharat Rekhi et al.
MODERN PATHOLOGY (2016)
Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group
Suzanne L. Wolden et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
David A. Rodeberg et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group
Abby R. Rosenberg et al.
EUROPEAN JOURNAL OF CANCER (2014)
Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F] Fluorodeoxyglucose Positron Emission Tomography
Dana L. Casey et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas
Douglas S. Hawkins et al.
PEDIATRIC BLOOD & CANCER (2013)
Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group
Beverly Raney et al.
JOURNAL OF PEDIATRIC SURGERY (2010)
Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group
David A. Rodeberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803
Carola A. S. Arndt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: The intergroup rhabdomyosarcoma study-IV experience - A report from the soft tissue sarcoma committee of the children's oncology group
Megan Burke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group
Jane L. Meza et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: Implications for the outcome
JA Ortega et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2000)
分享论文
